Patent US4087545A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4087545A Expired / Lapsed US ⏱️ 0.0 years remaining

Hexahydro-dibenzo[b,d]pyran-9-ones as antiemetic drugs

Assignee: Eli Lilly and Co
•
Filing: 1976-02-17
•
Granted: 1978-05-02
•
Expires: 1996-02-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Use of 1-hydroxy-3-alkyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones as antiemetic drugs.

Inventors

  • 👤 Robert A. Archer
  • 👤 Louis Lemberger

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 13:46
CPC Classifications
C; C07; C07D; C07D493/00; C07D493/02; C07D493/10; C07D311/00; C07D311/02; C07D311/04; C07D311/06; C07D311/08; C07D311/16; C07D311/78; C07D311/80

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 90 words
A process for providing prevention and treatment of emesis and nausea in mammals which comprises administering to a nauseated mammal an anti-emetic dose of a compound represented by the formula ##STR9## wherein R' is either C 7 -C 10 normal alkyl or is the group ##STR10## wherein R" is C 2 -C 7 alkyl and R v is H or methyl, wherein both R groups are identical and are H or methyl and wherein R'" is H or C 1 -C 4 alkanoyl, in an amount effective to prevent nausea.
Claim 2
Dependent Claim 90 words
A process for providing prevention and treatment of emesis and nausea in mammals which comprises administering to a nauseated mammal an anti-emetic dose of a compound represented by the formula ##STR9## wherein R' is either C 7 -C 10 normal alkyl or is the group ##STR10## wherein R" is C 2 -C 7 alkyl and R v is H or methyl, wherein both R groups are identical and are H or methyl and wherein R'" is H or C 1 -C 4 alkanoyl, in an amount effective to prevent nausea.
Claim 3
Dependent Claim 23 words
A process according to claim 1 in which a dose of from 0.1 to 100 mgs per day of the drug is administered.
Claim 4
Dependent Claim 23 words
A process according to claim 1 in which a dose of from 1 to 20 mgs. per day of the drug is administered.
Claim 5
Dependent Claim 16 words
A process according to claim 1 in which the drug is administered by the oral route.
Claim 6
Dependent Claim 11 words
A process according to claim 1 in which dl-trans-1-hydroxy-3-(1',1'-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one is administered.
Claim 7
Dependent Claim 11 words
A process according to claim 1 in which dl-trans-1-hydroxy-3-(1',2'-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one is administered.
Claim 8
Dependent Claim 11 words
A process according to claim 1 in which dl-trans-1-hydroxy-3-(1'-methylheptyl)-6,6a,7,8,10,10a-hexahydro-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one is administered.

References Cited (Backward Citations)

US3928598A Cited
US3953603A Cited
US3968125A Cited
US3987188A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-05-01 1981-10-31 1982-05-02 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-05-01 1985-10-31 1986-05-02 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-05-01 1989-10-31 1990-05-02 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag